Help us confirm that you're an expert
I have over 15 years of experience working in preclinical drug development, I led the preclinical development seed phase of 13 novel leads, covering small molecules and monoclonal antibodies. I am specialized in molecular pharmacology assessments, PK/ADME and CMC regulatory compliance and intellectual property rights in biotechnology companies.
Currently, as E2DG’s Chief Scientific Officer, I support our clients and collaborators to optimize and accelerate their R&D programs in oncology. E2DG offers professional assistance all along the drug development life cycle, from lead optimization to Phase I clinical trials in oncology.